Role of Haloperidol and Olanzapine in the treatment of Delirium
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Delirium
- Registration Number
- CTRI/2016/10/007331
- Lead Sponsor
- Government Medical College Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
1. Age of patients 18-75 years. 2) Patient should be verbally responsive. 3) Patients or caregiver must give written consent for the study
Exclusion Criteria
1) Mechanically ventilated or mute patients. 2) Patients of alcohol withdrawal delirium. 3) Patients having history of dementia. 4) Patients who had already been injected with antipsychotics in the emergency room or intensive care unit. 5) Patients having hypersensitivity reaction to haloperidol or olanzapine in past.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Confusion Assessment Method (CAM) <br/ ><br>2.Memorial Delirium Assessment Scale (MDAS) <br/ ><br>3.Simpson-Angus Scale (SAS) <br/ ><br>Timepoint: Every 24 hours till resolution of delirium <br/ ><br>
- Secondary Outcome Measures
Name Time Method 1.Confusion Assessment Method (CAM) <br/ ><br>2.Memorial Delirium Assessment Scale (MDAS) <br/ ><br>3.Simpson-Angus Scale (SAS) <br/ ><br>Timepoint: Every 24 hours till the resolution of Delirium